Table 5 Comparison of adverse events among the three groups (%).

From: Safety and efficacy of one-dose nocturnal levetiracetam for the treatment of self-limited epilepsy with centrotemporal spikes: a randomized clinical trial

Group

n

Adverse events

No adverse events

Group A

65

13(20.0)

52(80.0)

Group B

62

7(11.3)

55(88.7)

Group C

65

17(26.2)

48(73.8)

X2

-

4.540

P

-

0.103

Back to article page